On the basis of these findings, we reasoned that therapeutically targeting the GADD45β/MKK7 complex would selectively block the NF-κB survival function in MM cells, without affecting the pleiotropic and ubiquitous physiological functions of NF-κB. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.